Skip to main content



21-06-2021 | Rheumatology | News | Article

Studies evaluate effectiveness of IVIG, glucocorticoids for MIS-C

Two real-world studies published in The New England Journal of Medicine draw conflicting conclusions on the effectiveness of treatment regimens involving intravenous immunoglobulin and glucocorticoids for the treatment of multisystem inflammatory disease in children.

18-06-2021 | Rheumatology | News | Article

IL-17A inhibitors supported for axSpA in the UK

Click through for more information on these two NICE recommendations

16-06-2021 | Rheumatology | News | Article

Tofacitinib beneficial for COVID-19 pneumonia

Add-on treatment with the JAK inhibitor tofacitinib reduces the risk for death or respiratory failure among hospitalized patients with COVID-19 pneumonia who are not receiving mechanical ventilation, shows the STOP-COVID trial.

16-06-2021 | Rheumatology | News | Article

Biomarkers may distinguish hyperinflammatory syndromes in children

Two studies have identified serum biomarkers that could be used to differentiate between hyperinflammatory syndromes in children.

15-06-2021 | Rheumatology | News | Article

ACR issues guidelines for rheumatoid arthritis treatment

Click through for more information on the recommendations

14-06-2021 | Rheumatology | News | Article

Osteoarthritis linked to elevated risk for Parkinson’s disease

People with osteoarthritis have a significantly higher long-term risk for developing Parkinson’s disease than those without, researchers report.

11-06-2021 | Rheumatology | News | Article

COVID-19 antibody data reassuring for people with SLE

The majority of patients with systemic lupus erythematosus and confirmed COVID-19 are able to produce a durable antibody response to the infection, despite the use of immunosuppressants, US research suggests.

10-06-2021 | Rheumatology | News | Article

Inflammation not accurately reflected by tender joints in RA

Tender joints in patients with rheumatoid arthritis may not be a suitable indicator of inflammation, study findings show.

08-06-2021 | Rheumatology | News | Article

​​​​​​​EULAR issues recommendations on intra-articular therapies

EULAR has developed evidence-based recommendations on the use of intra-articular therapy in adult patients with peripheral arthropathies.

07-06-2021 | Rheumatology | News | Article

Upadacitinib beneficial in PsA patients with axial involvement

A pooled analysis of data from the SELECT-PsA-1 and SELECT-PsA-2 trials suggests that treatment with the JAK inhibitor upadacitinib improves axial symptoms in patients with psoriatic spondylitis.

07-06-2021 | Rheumatology | News | Article

BIOCOV study supports rituximab link to severe COVID-19

Further research confirming an association between rituximab and an increased risk for severe COVID-19 was reported at the EULAR 2021 Virtual Congress.

07-06-2021 | Rheumatology | News | Article

Real-world studies point to similar effectiveness of JAK inhibitors and biologics

Findings from two real-world studies presented at the EULAR 2021 Virtual Congress suggest that JAK inhibitors and biologics are similarly effective for the treatment of inflammatory arthritis.

06-06-2021 | Rheumatology | News | Article

​​​​​​​Genetic study points to causal link between gout and hypertension

A Mendelian randomization analysis presented at the EULAR 2021 Virtual Congress suggests that the association between gout and hypertension may have a causal basis.

06-06-2021 | Rheumatology | News | Article

Mavrilimumab shows potential for severe COVID-19

Inhibition of GM-CSF with mavrilimumab may represent a promising treatment option for patients with severe COVID-19 pneumonia and systemic hyperinflammation, suggest phase 2 study results.

05-06-2021 | Rheumatology | News | Article

Pfizer–BioNTech vaccine immunogenicity confirmed in patients with AIIRDs

Research confirms immunogenicity with the Pfizer–BioNTech COVID-19 vaccine in most patients with autoimmune inflammatory rheumatic diseases.

05-06-2021 | Rheumatology | News | Article

JUNIPERA: Secukinumab improves outcomes in juvenile PsA, ERA

Children and adolescents with juvenile psoriatic arthritis or enthesitis-related arthritis may benefit from treatment with the IL-17A inhibitor secukinumab, indicate phase 3 study results.

05-06-2021 | Rheumatology | News | Article

Patients with RMDs not at increased risk for severe COVID-19 vaccine side effects

Initial data from the COVAX Registry offer reassurance for patients with rheumatic and musculoskeletal diseases that adverse events with the COVID-19 vaccines are similar to those seen in the general population.

05-06-2021 | Rheumatology | News | Article

CV risk similar for gout treatments allopurinol and benzbromarone

Allopurinol and benzbromarone have comparable cardiovascular risk profiles in patients with gout, suggests research presented in a poster at the EULAR 2021 Virtual Congress.

05-06-2021 | Rheumatology | News | Article

Etanercept response clusters identified in patients with JIA

Researchers have found that children and young people with juvenile idiopathic arthritis can be categorized into five different groups according to their response to etanercept treatment.

05-06-2021 | Rheumatology | News | Article

Levilimab–methotrexate combination improves RA response rates

The addition of levilimab to methotrexate improves response rates among patients with rheumatoid arthritis who are resistant to methotrexate, show phase 3 SOLAR data presented in a poster at the EULAR 2021 Virtual Congress.